Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenabasum in Diffuse Cutaneous Systemic Sclerosis (Phase 3)
2017-000372-29Phase 3Unknown
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing Lenabasum 20 mg BID with Placebo (2 arms). Primary endpoint: ACR Provisional Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score at Week 52. Status: unknown.
02
Drugs
lenabasum
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2017-000372-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000372-29.